George Schroeder MD, MS, FACEP, FAAUCM- Founder & President of Global Renaissance Enterprises, Corp. in Canada, & NARMPRO , LLC in USA He has served as Clinical Assistant Professor of Emergency Medicine at the University of Central Florida College of Medicine and Executive Director of Medical Affairs for the American Academy of Urgent Care Medicine. He has 33 years of experience in Emergency / Urgent Care Medicine Appointed to the International Scientific Advisory Board - Magellan BioScience & serves on Board of Directors of American Academy of Urgent Care Medicine. He is a certified SSI Open Water SCUBA Diver

Emergency Medicine and Urgent Care Medicine, Marine toxins and Natural product Bioactive marine molecules with Biopharmaceutical potential

Emmanuel O. Akala, R. Ph., Ph.D. is a Professor of Pharmaceutics, Chair, Howard University Institutional Animal Care and Use Committee (IACUC) and Director, Laboratory for Nanomedicine, Drug Delivery, and Pharmaceutical & Biopharmaceutical Drug Products Design. His training is cosmopolitan and his curriculum vitae (CV) provides details of his professional training as a pharmacist and an immunization pharmacist (registered in Utah, Maryland, Washington DC and in Nigeria), a pharmacy professor, and a research scientist with bias for conventional and novel drug delivery systems. Professor Akala received B. Pharm. (Hons) degree and M.Sc. (Pharmaceutics) degree at The University of Ife (Now Obafemi Awolowo University), Ile-Ife, Nigeria and Ph.D. degree in Pharmaceutics at The University of Manchester, England (as a Commonwealth Scholar). He was a DAAD Fellow at the Institute of Biopharmaceutics and Pharmaceutical Technology, University of Munster, Germany, and an NIH Postdoctoral Fellow in Pharmaceutics and Bioengineering at The University of Utah, USA. He has worked as a pharmacist in Nigeria and USA, and as a Lecturer and Senior Lecturer in Pharmaceutics in Nigeria, as a Teaching Assistant in England, as a Laboratory Instructor and Research Associate in USA and Germany and as an Assistant Professor, Associate Professor and Professor of Pharmaceutics in USA.

His research interests includes Controlled Drug Delivery and Drug Targeting, Drug Formulation and Stability Studies, Pharmacokinetics in Pharmaceutical Dosage Form Design, Pharmacokinetics in Pharmaceutical Dosage Form Design, Drug Formulation and Stability Studies, Biomaterials, Biopharmecutical Application of Nanotechnology.

Dr. Anka G. Ehrhardt is a biophysicist with a doctorate degree in human physiology. She is currently working in the United States building and directing a team applying the latest technologies in support of the development of new live saving drugs.

Velvet Revolution in Biomarkers, Science and Business Drivers in Clinical Biomarkers

Dr. Tirotta has been an active member of Miami Children’s Hospital medical staff since 1991, practicing with the Department of Anesthesiology; he has served as the Director of Cardiac appointment with the Department of Anesthesiology at The University of Miami School of Medicine. Dr. Tirotta received his BA from Cornell University in 1982 and his MD from New York University School of Medicine in 1986. He also received an MBA degree from Columbia University in 1999. Dr. Tirotta completed his internship in Internal Medicine at SUNY at Stony Brook in 1987. He completed his residency training in anesthesiology at the University of Miami/Jackson Memorial Hospital in 1990; he sub-specialized in pediatric and cardiovascular anesthesia, including heart transplantation. He has been the Principal Investigator on a number of clinical drug/device trials, including on the ONQ Pain Buster, the muscle relaxant Zemuron, the procoagulant RiaSTAP, the Cardiotronic NICOM device and the AirPurge.

Cardiovascular anesthesia including heart transplantation

Pillhun Son earned his PhD from Texas Tech University in Organic and Computational Chemistry and then moved on to work on Material Science and Physical Chemsitry during his Postdoc. He has worked on several database building and information solution initiatives for CAS, including, CASREACT (CAS’s premier reaction database) and the all new Formulations information solution (set to launch mid 2017). Most recently, Pill also acheived a MS in Information Systems from Northwestern University.

Material Science and Physical Chemsitry

Anna Szemik-Hojniak is an associate professor (Molecular Photophysics), employed at the Faculty of Chemistry of the University of Wroclaw (Poland). She received her Ph.D in Radiochemistry and her post-doctoral research work she conducted in Belgium [ULB(Phys. Chem)-Solvay Found, dir. Noblist, prof.I.Prigogine; KULeuven-Radiochem.(Inst.Nucl.Sci.,Belg.At.En.Com.) and France (Centr, Nucl. Res,Strasbourg-CNRS). Her scientific interest is in Time-Resolved Emission Spectroscopy (Excited State Electron and Proton Transfer) of organic compounds for high - tech and Pharmaceutical Industry. Dr Szemik performs intensive internat. scientific collaboration with the research groups from Holland (awarded by KNAW and NOW, Europ.Laser Centre), Germany (Berlin), France (Saclay), Russia and Israel. In 2005, at the Faculty of Chemistry of the University of Wroclaw (Poland) she opened a new Laborarory of Molecular Photophysics. Since 1996, she participates in ICWES conferences (International Conference of Women Engineers and Scientists) and during the last 9 years she served as INWES Board Director (“Distinguished Service Award”-2011). In 2007, she organized International Symposium for Women Scientists and Engineers of New EU Countries and East Europe “Strategies for a Highly Skilled Global Workforce” (Letters of Congrats from EC-Directorate of Women in Science and from the Min.Sci.High Educ,-Poland). Anna publishes both the professional papers and those on Women in Science. She cooperates with EC (Directorate “Women in Research and Innovations”) for “Science: it is a girl thing” project (Letter of Congrats from the Polish Ministry of Science and High Education).

Pharmaceutical Industry, Excited State Electron and Proton Transfer

Dr O’Driscoll is a pharmacist with a PhD in microbiology and working as Professor in Robert Gordon University, Aberdeen since 2010. Her key research areas are novel antimicrobials, veterinary pharmacy, contact lenses, aseptic suite working and contamination control and water treatment.

Novel antimicrobials, Veterinary pharmacy, Pharmaceutical Industry

Pierre A. MORGON is Chief Executive Officer of AJ Biologics and Regional Partner for Switzerland at Mérieux Développement, and the Founder of MRGN Advisors. He is also Non-Executive Director to the Board of Theradiag as well as to the Board of Eurocine Vaccines. He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD, IMD and MCE executive programs. Pierre has over 28 years of experience in the pharmaceutical and biological industry and in healthcare IT, in marketing positions up to C-level global marketing strategy, and in operations up to general management. He has acquired direct experience with blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology), geographies (US, Europe, Japan, China, India, Emerging Markets) and organizations.

Pharmaceutical, biological industry and in healthcare

Dr Zi (Sophia) Gu is a Lecturer and National Health and Medical Research Council (NHMRC) Early Career Fellow in the School of Chemical Engineering at University of New South Wales (UNSW), Sydney. She obtained PhD from Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), Australia, in 2011, and she was awarded a NHMRC EC Fellowship in 2013 when she started her independent research at UQ prior to joining UNSW in 2016. Sophia has been working in multidisciplinary research areas that combine the knowledge and skills across nanotechnology and biomedicine, and has developed a targeted anti-restenotic therapy and built inorganic nanoparticle platforms for diagnosing and treating diseases. She published in high-impact journals including Advanced Materials, Biomaterials, Chemistry of Materials, Materials Horizons, and Journal of Controlled Release etc. Her recent awards include The Monash Engineering Women’s Leadership Award and Deputy Vice-Chancellor (Academic) Award. Her research group focuses on developing multifunctional nanomaterials for theranostic application (disease therapy and diagnosis

Nanoparticles for cancer treatment and diagnosis

Satyanarayana Somavarapu move to England came with the award of a Commonwealth Fellowship from the Association of Commonwealth Universities and he undertook a PhD at the University of Aston in Birmingham. In 2005 he was appointed as Academic Fellow at The School of Pharmacy and became a lecturer in 2010. He has over hundread publications, including fifty journal articles, over fifty peer-reviewed abstracts and several international conference presentations. He also has six patents on vaccine formulations. His research focus is on designing, understanding & developing technologies for novel nanocarrier systems in overcoming biological barriers for the targeted delivery of small therapeutic molecules and macromolecules (proteins, peptides, siRNA, miRNA) via the pulmonary route in the treatment of lung diseases (lung cancer, asthma, COPD) and ocular conditions.

Designing, understanding & developing technologies for novel nanocarrier systems in overcoming biological barriers for the targeted delivery of small therapeutic molecules and macromolecules (proteins, peptides, siRNA, miRNA) via the pulmonary route in the treatment of lung diseases (lung cancer, asthma, COPD) and ocular conditions.

Edwin Moore has 40 years of biopharmaceutical, pharmaceutical, and clinical diagnostic industry experience from global companies, Baxter Healthcare Corp and Abbott Laboratories, in R&D product development. Since retiring he has enjoyed research, teaching, and mentoring startup companies at University of Illinois, Champaign-Urbana campus, and consulting with BioPhia Consulting, Inc. He was a postdoc at University of Michigan, and received his PhD from Cornell University in Biochemistry, B.S. from University of Illinois in Biochemistry.

biopharmaceutical, pharmaceutical, and clinical diagnostic industry

Tatsuya TAKAGI has completed his Ph.D. at the age of 32 from Osaka University. At that time, he had been an Assistant Professor of School of Pharmaceutical Sciences, Osaka University for 5 years. Then, since 1993, he had worked for the Genome Information Research Center, Osaka University as an Associate Professor until he became a Professor of Graduate School of Pharmaceutical Sciences, Osaka University in 1998. He has published more than 150 papers in reputed journals and had served as Chairman of Division of Structure-Activity Relationship of the Pharmaceutical Society of Japan for three years (until March 2017)

Genome Information Research

Dr. Luke Fisher background brings twenty years of experience in scientific informatics solutions. Managing Pre-Sales, Post-Sales and working in Account Management has expanded my domain knowledge of scientific informatics and provided me the ability to maintain a successful track record. I have covered a broad range of clients including the world’s leading pharmaceutical, biotech, agricultural, chemicals, academic and government labs. I have extensive experience in scientific software solutions from the smaller scale deployment of point solutions like molecular modeling packages to the larger enterprise scale of ELNs, scientific workflow technologies, data content, analysis and visualization. My background also includes managing the support complexity of software integration strategies based on numerous mergers and acquisitions.

pharmaceutical, biotech, agricultural, chemicals, academic and government labs

Rick joined WuXi AppTec in 2015 to provide scientific leadership for 160 scientists in developability, formulation development, GMP manufacturing and is responsible for the execution of all parenteral and oral dosage form programs. Prior to joining WuXi, Rick was Global Head of Chemical and Pharmaceutical Profiling at Novartis, where he led the development and implementation of innovative dosage form designs and continuous manufacturing paradigms. Rick has led groups in formulation, research and development at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen and Baush & Lomb. In addition to his current position at WuXi, Rick is an adjunct professor at the Massachusetts College of Pharmacy.

Pharmaceutical Development

Michael Song is the head of Device Functionality, Safety and Digital Connectivity at MedImmune, a Member of the AstraZeneca Group. In his current role, he oversees device functionality and safety; primary container science and technology; biocompatibility; container closure integrity; and digital connectivity development. Prior to his current role, Michael was head of Device and Package Engineering department at Adello Biologics. He also has held key engineering and toxicology SME positions at Stryker and Kavlico, a member of Schneider Electric. Michael holds a BS in Electrical Engineering from Purdue University and PhD in Neuroscience and Toxicology from Iowa State University.

Device Functionality, Safety, and Digital Connectivity Dosage Form Design and Development BioPharmaceutical Development

Prof. Bijoy K Kuanr received the Ph.D. degree in "Microwave materials & Devices" in Electronic in 1993. He has more than 20 years of research experience in India as well as in various laboratories in Germany and USA. From 1994-96, he joined the Microwave Laboratory of Professor Dr. Güther Nimtz at University of Koeln, Germany as a Post-Doctoral Researcher. From 1999-2001 he worked with Professor Dr. Peter Grünberg - (Nobel Laureate - Physics 2007) as a guest scientist in GMR-Sensor project. In 2002 he joined University of Colorado at Colorado Springs as a senior Researcher till 2013. His main research deals with electromagnetic theory and measurement techniques applied to materials, devices, and circuits at microwave, millimeter-wave.

Drug Delivery Chemistry

Experienced Professor with a demonstrated history of working in the higher education industry. Skilled in Pharmaceutics, Lecturing, Educational Technology, Curriculum Development, and Academic Writing. Strong education professional with a PhD (Joint Supervision with Faculty of Pharmacy, Alazhar University, Egypt) focused in Pharmaceutics from School of Pharmacy, University of Wisconsin-madison.

Physical Pharmacy, Stability and kinetics, Liquid dosage forms, Solid Dosage forms, Drug delivery, Biopharmaceutics and Pharmacokinetics.

Ebtisam Aldaais is one of the first Saudi women that have a Ph.D. in Biomedical Engineering. She earned her Ph.D. degree in 2016 from the University of South Carolina. In 2012, she got her Master’s degree in Physics. Dr. Aldaais has more than 18 years of experience in teaching, developing material courses, research, performing quality assurance for LINAC machines, and modeling polymeric biomaterials and drug delivery systems. She works as an assistant professor at the biomedical engineering department at Imam Abdulrahman Bin Faisal University, as well as a visiting assistant professor at the department of physics & astronomy at University of South Carolina.

Performing quality assurance for LINAC machines, and modeling polymeric biomaterials and drug delivery systems

Rongshi Li is a Professor of Chemistry and Medicinal Chemistry, UNMC Center for Drug Discovery, Department of Pharmaceutical Sciences, College of Pharmacy; Cancer Genes and Molecular Regulation Program, Fred & Pamela Buffett Cancer Center; and Center for Staphylococcal Research, University of Nebraska Medical Center. Dr. Li spent 14 years in industry advanced from Scientist to Senior Vice President after postdoctoral training at University of California San Francisco. Dr. Li began his academic career in 2008 at H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. In 2013, he was recruited to University of Nebraska Medical Center. Dr. Li received 2013 Grants Award, 2014 and 2016 New Inventions, and 2016 Distinguished Scientist Award. Dr. Li has published over 100 peer-reviewed articles, invited reviews, US and PCT patents, edited books, book chapters, and editorial. He delivered over 100 lectures and presentations in the universities and research institutions throughout the world, and in national and international symposia as invited and keynote speakers.

Chemistry and Medicinal Chemistry

Dr. Satinder Ahuja successfully managed development of many new drugs at Novartis Corporation for over 25 years in a number of leadership positions that led to earnings of billions of dollars. His expertise is recognized worldwide in chromatography and separations, especially in the area of ultratrace analyses, chiral separations, and characterization of contaminants by various techniques. As President of Ahuja Consulting, he has advised major pharmaceutical companies in the US and abroad on new drug development and on green chemistry solutions to environmental issues. He has given plenary lectures worldwide, won awards, and published numerous papers and over twenty books.

Ultratrace analyses

Wei Zhang, PhD Professor and Director of the Center for Green Chemistry Department of Chemistry University of Massachusetts Boston

Organic Chemistry and Green Chemistry

Wei Li, Ph.D. Professor and Faculty Director of Instrument Facility University of Tennessee Health Science Center. His research areas include drug-targeting, nanoparticles, drug transport across the blood-brain barrier using nanoparticles, microspheres, trans-dermal transport, polymeric drug delivery systems, adjuvants for vacccines, solid solutions, stability testing by microcalorymetry, and container materials. He has over 300 publications.

His research areas include drug-targeting, nanoparticles, drug transport across the blood-brain barrier using nanoparticles, microspheres, trans-dermal transport, polymeric drug delivery systems, adjuvants for vacccines, solid solutions, stability testing by microcalorymetry, and container materials. He has over 300 publications.

Carlos Feleder was selected by the Italian Ministry of Health to review grant applications for biomedical research. He reviews grants in the fields of neuroscience, immunology, and endocrinology. Dr. Feleder servers as a Principal Investigator at the Albany Center for Computational Nano-Neuroscience at The State University of New York. He has done his M.D. from School of Medicine, University of Buenos Aires, Buenos Aires, Argentina and completed his PhD. from The Frauenklinik fur Experimentelle Endokrinologie, University George-August, Gottingen, Germany; and Department of Physiology, School of Medicine, University of Buenos Aires, Argentina

Dr. Feleder has a long-standing interest in uncovering the mechanisms underlying the body's response to immune challenges, i.e., how the central nervous system controls the physiologic functions that protect the body from the harmful effects of infectious agents. In 2008, Dr. Feleder was awarded a three year research grant totaling $231,000 from the National Institutes of Health (NIH) to study the effects of the spleen in managing fever.

Asunción Barbero was born in Burgos, Spain. She studied Chemistry at the University of Valladolid, and received her PhD degree at the same university working with Prof. Pulido. She joined Prof. Ian Fleming’s group at the University of Cambridge as Marie Curie fello for two years working in the study of stereocontrol in organic synthesis using silicon chemistry. She came back to Valladolid as Assistant Professor, was promoted to Associate Professor in 2001 and obtained the spanish habilitation to full Professor in 2012. In 2013 she was appointed as Coordinator of the Grade of Chemistry of the University of Valladolid. She has co-authored around 50 international scientific publications and has delivered several invited and plenary lectures. Her current interests include the study of the silyl-cupration of multiple bonds and its application to the synthesis of natural and related products.

Organic synthesis, synthesis of heterocycles, Organometallic synthesis, Synthesis of carbocycles, synthesis of natural products

Research activities developed within Catherine Guillou’s group are centred on the development of new methodologies, their application to the total synthesis of biologically active natural products and the design of enzyme inhibitors involved in cancer and Alzheimer’s disease. She is co-authors of 58 publications and 8 patents.

Chemistry

Dr Guallar completed his PhD in collaboration between UAB (Spain) and UCBerkeley (USA) and postdoctoral studies from Columbia University. After an assistant professor position at Washington University School of Medicine (USA), he was awarded an ICREA professor position at the Barcelona Supercomputing Center. He is also founder of Nostrum Biodiscovery. He has published more than 100 papers in reputed journals and has been the recipient of presitioug grants like an Advanced ERC from the European Union.

Chemistry, Drug designing, High performance computing and improved 2D/3D visualization techniques.

Dr. Bhargava Karumudi is a research specialist at University of Illinois, Chicago in the field of medicinal chemistry. He has completed his postdoctoral in medicinal chemistry in 2014 at University of Illinois.

Organic Synthesis/Medicinal Chemistry, Chemical Biology, Chemistry of natural products with interesting biological activity, Natural products drug discovery, developing new probes to explore promising drug targets/photoaffinity labeling, LC-MS/MS.

Praveen S Hiremath is currently working as a Principal Scientist at Pharmaceutics International Inc Pii. He has completed Masters and doctoral studies and PhD in Pharmaceutics. Dr. Hiremath has worked in renowned Pharmaceutical companies like Astra Zeneca and Ranbaxy. Also he has Postdoctoral experience in Pharmaceutical drug delivery and formulation from Western University of Health Sciences, California, USA. Dr. Hiremath has published several research articles in peer reviewed international journals. He has extensively presented his research at international conferences/symposiums. Dr. Hiremath has been an invited speaker at international conferences. He has been invited to edit books in Pharmaceutical formulation and technology. Dr. Hiremath serves on editorial board of Journal of Bioequivalence and Bioavailability, Journal of Bioanalysis and Biomedicine and Research in Pharmaceutical Biotechnology. He is a full member of Sigma Xi Scientific Research Society and member of AAPS.

Oral drug delivery Pharmaceutical formulation development Controlled release drug delivery systems Pharmaceutical intellectual property (IP) Lipid based drug delivery systems Pharmaceutical technology Quality-by-design (QBD).

Dr. Sahar Ahmed is an Assistant Professor at the Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, KSA. She is Currently on leave from the Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Egypt. Dr. Ahmed received her B.Sc. from the Faculty of Pharmacy, Assiut University, Egypt, and then her M.Sc. From the same Faculty. She subsequently got her Ph.D. from the Faculty of Pharmacy, University of Alberta, Canada in 2010 under the supervision of Dr. K. Kaur followed by one year of a postdoc at the same Faculty. She has participated in many international conferences and published 15 publications in international journals and one chapter book.

Organic Synthesis/Medicinal Chemistry, Chemical Biology, Chemistry of natural products with interesting biological activity, Natural products drug discovery, developing new probes to explore promising drug targets/photoaffinity labeling, LC-MS/MS.

Daisuke Yamamoto has completed his PhD in 2006 at Kitasato University (Prof. Toshiaki Sunazuka). Subsequently, he became a researcher at the Kitasato Institute (Prof. Satoshi Ōmura) and joined the group of Prof. Barry M. Trost at Stanford University, as a postdoctoral fellow. In 2008, he started his academic career as an Assistant Professor at Kitasato University. His research focuses on the development of redox reactions with attendant applications in biologically active molecules.

Chemistry: development of redox reactions and applications in biologically active molecules

Prof. Dr. Kreuter studied pharmacy from 1968 to 1971 at the Philipps-University Marburg, Germany. He did his Ph.D. from 1972 to 1974 at the Eidgenössische Technische Hochschule Zürich (ETH, Swiss Federal Institute of Technology) under the supervision of Prof. P. Speiser. His doctoral thesis was honoured with the ETH-Medal. He received his habilitation (D.Sc.) in 1982 at the ETH. In 1977 he worked as a postdoc with Prof. T. Higuchi in Lawrence, Kansas, U.S.A. and in 1979 with Prof. W. I. Higuchi in Ann Arbor, Michigan, U.S.A. In 1983 he was a guest professor at the University of Wisconsin, Madison, U.S.A. 1984 he became associate professor in pharmaceutical technology at the Johann Wolfgang Goethe-University in Frankfurt. Simultaneously he was offered the position of a full professor in pharmaceutical technology in Vienna but remained in Frankfurt. In 1990 he became full professor in Frankfurt. Twice he was dean, 1988/89 and 1997/98. In addition, from 1987 to 1990 he was Governor of the Controlled Release Society. He is recipient of the APV-Price 1981, the PPD Award of the Japanese Society of Powder Technology 2009, the Takeru and Aja Higuchi Honorary Lecture Award of the Japanese Academy of Pharmaceutical Sciences 2010, the Best Paper Award and the Most Cited Paper Award of the European Journal of Pharmaceutics and Biopharmaceutics in 2000 and in 2012, respectively, and the Jorge Heller Outstanding Paper Award of the Journal of Controlled Release 2009.

His research areas include drug-targeting, nanoparticles, drug transport across the blood-brain barrier using nanoparticles, microspheres, trans-dermal transport, polymeric drug delivery systems, adjuvants for vacccines, solid solutions, stability testing by microcalorymetry, and container materials. He has over 300 publications.

Wei Zhang, PhD Professor and Director of the Center for Green Chemistry Department of Chemistry University of Massachusetts Boston

Chemistry

Wei Li, Ph.D. Professor and Faculty Director of Instrument Facility University of Tennessee Health Science Center 881 Madison Avenue, room 561 Memphis, TN 38163 901-448-7532

Instrument Facility

Hiroshi Maeda is a world renowned expert in macromolecular therapeutics. He created the world first polymeric-conjugate drug, SMANCS, approved for treatment of hepatoma in Japan. Consequently, he discovered the concept of EPR effect of macromolecular-drugs, ubiquitous mechanism for solid tumor selective targeting of polymeric drugs. He received MS, University of California, Devis, Fulbright student, Ph.D., M.D., Tohoku University. He published more than 450 papers in reputed journals. He was awarded Lifetime-Achievement-Award at Royal-Pharmaceutical-Society, Princess-Takamatsu-Award in Cancer Research, Tomizo-Yoshida-Award, highest award of Japan-Cancer-Assoc., and also selected as most cited influential scientist in pharmacology by Thomson Reuters 2014, and H-index of 89.

His key areas of research includes concept of EPR effect of macromolecular-drugs, ubiquitous mechanism for solid tumor selective targeting of polymeric drugs. He created the world first polymeric-conjugate drug, SMANCS, approved for treatment of hepatoma in Japan

Frank M. Boeckler received his Ph.D. in Medicinal Chemistry from the University of Erlangen (Germany) in 2004 under supervision of Prof. Peter Gmeiner. He is specialized in computational chemistry and drug design, ranging from QM methods to in silico screening. In 2006, he joined Prof. Sir Alan R. Fersht at the MRC Center for Protein Engineering in Cambridge/UK as Marie Curie fellow and discovered there p53 mutant stabilizers as potential new cancer therapeutics. While working in Cambridge at the interface of experiment and theory, he focused on molecular biology and biophysics. In 2008, he was appointed as Professor (W2tt) for Bioanalytics at Ludwig-Maximilians University (LMU) Munich. In 2010, he moved to Eberhard Karls University Tubingen as Professor for Medicinal Chemistry/Drug Design, where he now heads the Laboratory for Molecular Design & Pharmaceutical Biophysics. Since 2014, he is also member of the Center for Bioinformatics Tubingen. He received several awards, including the Klaus-Grohe Award in Medicinal Chemistry, the Research Award of the Dornhecker Foundation and the PHOENIX Pharmazie-Wissenschaftspreis. In 2014, he was announced to be runner-up for the EFMC Prize for a Young Medicinal Chemist in Academia. His work is dedicated to understanding molecular interactions, particularly -hole bonding effects, as the foundation for chemical biology and drug research and to apply theoretical, chemical, biological, structural and biophysical methods to cancer research, particularly, for targeting the human kinome and the extensive p53 network.

• Understanding molecular interactions particular focus is halogen bonding, an innovative, bifunctional interaction. In drug research by generating tools, models, strategies and concepts for molecular design and fragment-based screening. Diversity-optimized and target-focused halogen-enriched fragment libraries (HEFLibs), use medicinal chemistry in combination with structural biology and computational chemistry for lead optimization of HEFLibs. • Develop and optimize biophysical and computer-aided techniques for screening, innovative assay formats, based on semi-automated titration, magnetic beads, and solid-phase synthesis by plate-spotting. With DEKOIS2.0, we have established tools for benchmarking of virtual screening strategies. • Extending the idea of molecular design to structured therapeutic peptides, developing a chemical tool-kit that can be used for selecting antibody-like, structured peptides, such peptides will be useful for therapeutic, diagnostic, analytical procedures, because they can be easily functionalized or linked to proteins, ligands, materials, radioisotopes, etc. • He is particularly interested in innovative therapeutic concepts in oncology, including individualized therapy und novel targets: e.g. p53 mutant rescue and therapeutic intervention in the p53 pathway; studying the paradigm of molecular chaperones for protein-(mis)folding diseases, targeting protein-protein interactions, kinase polypharmacology, epigenetic targets, etc.

Asunción Barbero was born in Burgos, Spain. She studied Chemistry at the University of Valladolid, and received her PhD degree at the same university working with Prof. Pulido. She joined Prof. Ian Fleming’s group at the University of Cambridge as Marie Curie fello for two years working in the study of stereocontrol in organic synthesis using silicon chemistry. She came back to Valladolid as Assistant Professor, was promoted to Associate Professor in 2001 and obtained the spanish habilitation to full Professor in 2012. In 2013 she was appointed as Coordinator of the Grade of Chemistry of the University of Valladolid. She has co-authored around 50 international scientific publications and has delivered several invited and plenary lectures. Her current interests include the study of the silyl-cupration of multiple bonds and its application to the synthesis of natural and related products.

Organic synthesis, synthesis of heterocycles, Organometallic synthesis, Synthesis of carbocycles, synthesis of natural products

Carlos Feleder was selected by the Italian Ministry of Health to review grant applications for biomedical research. He reviews grants in the fields of neuroscience, immunology, and endocrinology. Dr. Feleder servers as a Principal Investigator at the Albany Center for Computational Nano-Neuroscience at The State University of New York. He has done his M.D. from School of Medicine, University of Buenos Aires, Buenos Aires, Argentina and completed his PhD. from The Frauenklinik fur Experimentelle Endokrinologie, University George-August, Gottingen, Germany; and Department of Physiology, School of Medicine, University of Buenos Aires, Argentina

Dr. Feleder has a long-standing interest in uncovering the mechanisms underlying the body's response to immune challenges, i.e., how the central nervous system controls the physiologic functions that protect the body from the harmful effects of infectious agents. In 2008, Dr. Feleder was awarded a three year research grant totaling $231,000 from the National Institutes of Health (NIH) to study the effects of the spleen in managing fever.

Dr Laurent Désaubry is a CNRS research director in the University of Strasbourg in France (website: http://desaubry.u-strasbg.fr/) and professor at Tianjin University of Science and Technology (TUST) in China. He is currently editor and board member of Frontiers in Chemistry, Medicinal Chemistry and Advances in Oncology Research and Treatments. In 1992, he received a Ph.D. degree in medicinal chemistry from Strasbourg University. From 1992 to 1996, he worked as a postdoctoral fellow at SUNY at Stony Brook, USA. He made another post-doctoral internship in Prof. Pierre Chambon’s laboratory before to get a CNRS Research Senior Scientist at the University of Strasbourg-CNRS. He was promoted CNRS research director (corresponds to full professor) in 2014, and became also professor at TUST in 2015.

Medicinal Chemistry and Advances in Oncology Research and Treatments

Dr. Bhargava Karumudi is a research specialist at University of Illinois, Chicago in the field of medicinal chemistry. He has completed his postdoctoral in medicinal chemistry in 2014 at University of Illinois.

Organic Synthesis/Medicinal Chemistry, Chemical Biology, Chemistry of natural products with interesting biological activity, Natural products drug discovery, developing new probes to explore promising drug targets/photoaffinity labeling, LC-MS/MS.

Praveen S Hiremath is currently working as a Principal Scientist at Pharmaceutics International Inc Pii. He has completed Masters and doctoral studies and PhD in Pharmaceutics. Dr. Hiremath has worked in renowned Pharmaceutical companies like Astra Zeneca and Ranbaxy. Also he has Postdoctoral experience in Pharmaceutical drug delivery and formulation from Western University of Health Sciences, California, USA. Dr. Hiremath has published several research articles in peer reviewed international journals. He has extensively presented his research at international conferences/symposiums. Dr. Hiremath has been an invited speaker at international conferences. He has been invited to edit books in Pharmaceutical formulation and technology. Dr. Hiremath serves on editorial board of Journal of Bioequivalence and Bioavailability, Journal of Bioanalysis and Biomedicine and Research in Pharmaceutical Biotechnology. He is a full member of Sigma Xi Scientific Research Society and member of AAPS.

Oral drug delivery Pharmaceutical formulation development Controlled release drug delivery systems Pharmaceutical intellectual property (IP) Lipid based drug delivery systems Pharmaceutical technology Quality-by-design (QBD).

Rafat M Mohareb is Head of Organic Chemistry department Faculty of Pharmacy Modern Sciences and Arts University Professor of Organic Chemistry at Department of Chemistry faculty of Science Giza, Egypt. He got his Ph D Organic Chemistry on 1984 Cairo university Full professor of Organic chemistry 1994 Visiting Professor at UC Berkeley University State of California USA from 1999- 2002 Visiting Professor At Kuwait University 19951996. He was Humboldt fellows in Germany in 1988, 1989, 1993, 1995, 1998, 2003, 2006 and 2009. He received the price of encouragement of research work from Egypt 1995. He published more than 108 Scientific publications in International journals. He Supervised more than 5 PhD M Sc Theses.

Synthesis of new heterocyclic compounds with different pharmaceutical uses. Heterocyclizations of some Human Hormones followed by application of the synthesized compounds in Medicinal chemistry.Synthesis new dyes and their applications towards different fabrics.Recently his research focused on synthesizing antitumor agents.

Dr. Sahar Ahmed is an Assistant Professor at the Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, KSA. She is Currently on leave from the Department of Medicinal Chemistry, Faculty of Pharmacy, Assiut University, Egypt. Dr. Ahmed received her B.Sc. from the Faculty of Pharmacy, Assiut University, Egypt, and then her M.Sc. From the same Faculty. She subsequently got her Ph.D. from the Faculty of Pharmacy, University of Alberta, Canada in 2010 under the supervision of Dr. K. Kaur followed by one year of a postdoc at the same Faculty. She has participated in many international conferences and published 15 publications in international journals and one chapter book.

Her research areas include Organic Synthesis/Medicinal Chemistry, and Cancer Targeting Peptides.